Provided by Tiger Trade Technology Pte. Ltd.

Palisade Bio Inc.

1.35
-0.1000-6.90%
Post-market: 1.360.0100+0.74%19:30 EDT
Volume:4.77M
Turnover:6.54M
Market Cap:234.90M
PE:-6.70
High:1.46
Open:1.44
Low:1.32
Close:1.45
52wk High:2.86
52wk Low:0.9631
Shares:174.00M
Float Shares:130.00M
Volume Ratio:1.04
T/O Rate:3.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2015
EPS(LYR):-0.3014
ROE:-51.37%
ROA:-32.98%
PB:1.93
PE(LYR):-4.48

Loading ...

Palisade Bio to present clinical, translational data for PALI-2108 at UEG Week

TIPRANKS
·
Sep 28

Palisade Bio Says Phase 1b Study Shows Early Clinical, Biomarker Gains for PALI-2108 in Fibrostenotic Crohn’s Disease

Reuters
·
Sep 28

Palisade Bio Wins Health Canada Clearance for Ascentra-UC Phase 2 Trial of PALI-2108

Reuters
·
Sep 23

Palisade Bio Expands Global Phase 2B Ascentra-Uc Program with Health Canada Cta Clearance

THOMSON REUTERS
·
Sep 23

Palisade Bio Price Target Maintained with a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 23

Palisade Bio Wins FDA IND Clearance for PALI-2108 Crohn’s Disease Phase 2 Trial

Reuters
·
Sep 22

Palisade Bio - First Patient Dosing Targeted for Q1 2027; Efficacy Readout Targeted for Q1 2028

THOMSON REUTERS
·
Sep 22

Palisade Bio to Present at Stifel Virtual Immunology and Inflammation Forum

Reuters
·
Sep 22

Palisade Bio to Join Wells Fargo, Morgan Stanley and H.C. Wainwright Healthcare Investor Conferences

Reuters
·
Sep 03

Maxim Group Sticks to Its Buy Rating for Palisade Bio (PALI)

TIPRANKS
·
Aug 12

Palisade Bio (PALI) Receives a New Rating from B. Riley Securities

TIPRANKS
·
Aug 12

Imunon Q2 Net Loss Widens Slightly as R&D Costs Rise

Reuters
·
Aug 11

Palisade Bio (PALI) Receives a Buy from Oppenheimer

TIPRANKS
·
Aug 11

Palisade Bio Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 11

Palisade Bio Q2 EPS $(0.05), Inline, Sales $500.000K

Benzinga Earnings
·
Aug 11

DiaMedica Q2 Net Loss Widen Less than Expected

Reuters
·
Aug 11

Palisade Bio Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 11

Palisade Bio Q2 FY26 Net Loss Widens 280% to $10.57 Million

Reuters
·
Aug 11

Palisade Bio Q2 EPS USD -0.05

THOMSON REUTERS
·
Aug 11

Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pali-2108 into Phase 2 Development

THOMSON REUTERS
·
Aug 11